# Shared Resources Core-Viral Vector Core

> **NIH NIH P50** · UNIVERSITY OF WASHINGTON · 2024 · $158,609

## Abstract

Project Summary – Resource (Vector) Core
The Viral Vector Core was established in 2003 to meet the emerging interest in using AAV & lentiviral vectors
for muscle gene transfer. The required specialized techniques and reagents prevented most labs from being
able to generate the high titer and enormous quantities of vectors needed for systemic gene delivery, challenges
that remain today. Consequently, a Viral Vector Core was established to generate vectors for Wellstone Centers,
but which has been expanded to allow access to a broader range of users via a recharge mechanism. This
Vector Core is our Scientific Research Resource Core. The Core provides high quality preparations of viral and
plasmid vectors to facilitate research related to the muscular dystrophies. Services offered by the Core include
vectors, reagents, consulting, and training related to vector production. This includes production of adeno-
associated and lentiviral vectors and muscular dystrophy related reagents (cell lines, vector backbones,
protocols, antibodies etc) for members of this Center as well as laboratories in the US and across the World to
support their efforts related to gene transfer and gene therapy for the muscular dystrophies. The Principle
Investigator is Dr. Joel Chamberlain, who has worked closely with Core personnel on AAV and retroviral vectors
for more than 15 years. The Core has established protocols and acquired reagents for lentiviral and adeno-
associated viral vectors, particularly AAV6, 8 and 9, but also for other pseudotyped vectors including AAV1, 2,
5, 7 and several recently identified myotropic (e.g. AAVMyo) capsids. We also have numerous muscle cDNAs,
such as for dystrophin and utrophin, muscle regulatory cassettes and antibodies that are available via this Core
lab, as well as DM1, DUX4 and associated RNAi vectors. We provide high quality, high titer preparations of AAV
and lentiviral vectors and also encourage users to visit the Core to learn, or request, our methods. Vectors and
reagents are provided to members of our Wellstone Center using funds from this Core, and to other muscular
dystrophy researchers on a recharge basis at cost. Training services allow investigators to apply methods for
production and purification of viral vectors in their own labs as desired, and will be advertised via the Center Web
site. Consulting will be available to guide the use of AAV and lentiviral vectors. Finally, we provide reagents (such
as vector backbones, plasmids, antibodies) that have been developed by members of this Wellstone Center to
outside labs.

## Key facts

- **NIH application ID:** 10922773
- **Project number:** 5P50AR065139-11
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** JOEL R CHAMBERLAIN
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $158,609
- **Award type:** 5
- **Project period:** 2014-05-07 → 2028-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10922773

## Citation

> US National Institutes of Health, RePORTER application 10922773, Shared Resources Core-Viral Vector Core (5P50AR065139-11). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10922773. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*